Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact

被引:173
作者
Brooklyn, John R. [1 ]
Sigmon, Stacey C. [1 ,2 ]
机构
[1] Univ Vermont, Dept Psychiat, Burlington, VT USA
[2] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA
基金
美国国家卫生研究院;
关键词
buprenorphine; hub-and-spoke system; opioid dependence; opioid use disorder; treatment; MAINTENANCE TREATMENT; BUPRENORPHINE TREATMENT; DEPENDENT PATIENTS; NONMEDICAL USE; UNITED-STATES; ASSOCIATION; EXPERIENCES; PREDICTORS; COSTS; ABUSE;
D O I
10.1097/ADM.0000000000000310
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Opioid use disorders (OUDs) are reaching epidemic proportions in the United States, and many geographic areas struggle with a persistent shortage in availability of opioid agonist treatment. Over the past 5 years, Vermont addiction medicine physicians and public health leaders have responded to these challenges by developing an integrated hub-and-spoke opioid treatment network. Methods: In the present report, we review the development, implementation, and impact of this novel hub-and-spoke model for expanding OUD treatment in Vermont. Results: Vermont's hub-and-spoke system has been implemented state-wide and well-received by providers and patients alike. Adoption of this model has been associated with substantial increases in the state's OUD treatment capacity, with Vermont now having the highest capacity for treating OUD in the United States with 10.56 people in treatment per 1000. There has been a 64% increase in physicians waivered to prescribe buprenorphine, a 50% increase in patients served per waivered physician, and a robust bidirectional transfer of patients between hubs and spokes based upon clinical need. Challenges to system implementation and important future directions are discussed. Conclusions: Development and implementation of a hub-and-spoke system of care has contributed substantially to improvements in opioid agonist treatment capacity in Vermont. This system may serve as a model for other states grappling with the current opioid use epidemic.
引用
收藏
页码:286 / 292
页数:7
相关论文
共 42 条
[1]   Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans [J].
Amass, L ;
Bickel, WK ;
Crean, JP ;
Blake, J ;
Higgins, ST .
PSYCHOPHARMACOLOGY, 1998, 136 (03) :217-225
[2]  
[Anonymous], OP
[3]  
[Anonymous], VERM MED HOM
[4]   Counselors' experiences treating methadone-maintained patients with chronic pain: A needs assessment study [J].
Barry, Declan T. ;
Bernard, Matthew J. ;
Beitel, Mark ;
Moore, Brent A. ;
Kerns, Robert D. ;
Schottenfeld, Richard S. .
JOURNAL OF ADDICTION MEDICINE, 2008, 2 (02) :108-111
[5]  
Becker WC., 2006, SUBST ABUS, V26, P15
[6]   Non-medical use, abuse and dependence on prescription opioids among US adults: Psychiatric, medical and substance use correlates [J].
Becker, William C. ;
Sullivan, Lynn E. ;
Tetrault, Jeanette M. ;
Desai, Rani A. ;
Fiellin, David A. .
DRUG AND ALCOHOL DEPENDENCE, 2008, 94 (1-3) :38-47
[7]   Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients [J].
Bickel, WK ;
Amass, L ;
Crean, JP ;
Badger, GJ .
PSYCHOPHARMACOLOGY, 1999, 146 (02) :111-118
[8]   Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States [J].
Birnbaum, Howard G. ;
White, Alan G. ;
Schiller, Matt ;
Waldman, Tracy ;
Cleveland, Jody M. ;
Roland, Carl L. .
PAIN MEDICINE, 2011, 12 (04) :657-667
[9]   Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study [J].
Bukten, Anne ;
Skurtveit, Svetlana ;
Waal, Helge ;
Clausen, Thomas .
ADDICTIVE BEHAVIORS, 2014, 39 (10) :1504-1509
[10]  
Casper K, 2016, AM ASS TREATMENT OPI, P2